Author: Newsdesk

SOUTH SAN FRANCISCO, Calif., Nov. 17, 2020 (GLOBE NEWSWIRE) — Fluidigm Corporation (Nasdaq:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, today announced COVID-19 Community Connect, a program to link federal, state and local governmental entities, public health agencies, academic institutions, workforces, individuals and a network of high-complexity labs to deliver saliva-based COVID-19 testing.

As demand for noninvasive saliva-based COVID-19 testing increases, Fluidigm is serving as a hub to connect interested communities with testing providers.

“Since announcing our Emergency Use Authorization for saliva-based PCR testing in late August, we have seen tremendous interest in our testing technology,” said Chris Linthwaite, Fluidigm President and CEO. “We created the Community Connect program to organize a system for assessing needs, recruiting lab partners and building a service ecosystem for delivering timely results. This model is proving to be an effective and scalable way to get the greatest number of our saliva-based COVID-19 tests to critical populations in communities across the United States.

“We have seen healthy adoption and growing demand for saliva-based testing with strong new instrument placements in clinical labs and public health and academic medical centers,” continued Linthwaite. “With many of the inquiries we receive, the community seeking our saliva test does not have access to appropriate lab facilities. To address this need, we developed the Community Connect program to match demand with testing supply. One example of this partnership model is an award to a partner testing lab for testing services around the federal surge testing effort under the U.S. Department of Health and Human Services Community-Based Testing Site program.

“We have been building a network of partner labs for a number of weeks, and we welcome additional partners as well as general inquiries from groups seeking reliable, cost-effective and easy-to-administer tests.”

In late August, Fluidigm received Emergency Use Authorization from the U.S. Food and Drug Administration for the Advanta™ Dx SARS-CoV-2 RT-PCR Assay, an extraction-free saliva-based test to detect nucleic acid from the SARSCoV2 virus. The assay does not require collection via invasive nasopharyngeal swab. The company’s clinical study submitted to the FDA demonstrated 100 percent agreement between saliva results from the Advanta assay and results from paired nasopharyngeal samples tested with authorized assays.

As an example of the types of connections Fluidigm is creating, Phase2 Labs of Nashville, Tennessee, has adopted the Advanta assay to market COVID-19 testing services to corporate and governmental entities, nursing facilities and on-location film crews.

“Phase2 is honored to collaborate with Fluidigm and other trusted partners to provide critically needed testing capacity to a range of organizations relying on COVID-19 tests to make strategic decisions about safety,” said Steven E. Kress, co-founder and CEO of Phase2 Labs.

“The saliva-based approach offers a simple, accurate, pain-free option for PCR COVID-19 testing, and Phase2 can deliver results within 24 to 48 hours. Based in Nashville, we’re within close reach of half the U.S. population, enabling us to be vital community partners in making a meaningful difference in this health crisis.”

The Advanta Dx SARS-CoV-2 RT-PCR Assay on the high-throughput Fluidigm® Biomark™ HD system features an integrated testing platform and a reliable supply chain that CLIA laboratories can combine with commonly available automation platforms.

Development, commercialization and implementation of the Advanta Dx SARS-CoV-2 RT-PCR Assay are supported by a $34 million definitive contract with the National Institutes of Health under the agency’s Rapid Acceleration of Diagnostics (RADx) initiative. The RADx initiative fast-tracks development and commercialization of innovative technologies to significantly increase U.S. testing capacity for SARS-CoV-2.

The Fluidigm RADx project is supported by the NIH Rapid Acceleration of Diagnostics initiative and has been funded in whole or in part with federal funds from the National Institute of Biomedical Imaging and Bioengineering, National Institutes of Health, Department of Health and Human Services, under contract No. 75N92020C00009.

Learn more about COVID-19 Community Connect: go.fluidigm.com/community-connect

Intended Use

The Advanta Dx SARS-CoV-2 RT-PCR Assay is a real-time reverse transcription (RT) PCR test intended for the qualitative detection of nucleic acid from SARS-CoV-2 in saliva specimens collected without preservatives in a sterile container from individuals suspected of COVID-19 by their health care providers. Testing is limited to laboratories that are certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C. §263a, and meet requirements to perform high-complexity tests. Results are for the identification of SARS-CoV-2 RNA. The SARS-CoV-2 RNA is generally detectable in saliva specimens during the acute phase of infection. Positive results are indicative of the presence of SARS-CoV-2 RNA; clinical correlation with patient history and other diagnostic information is necessary to determine patient infection status. Positive results do not rule out bacterial infection or co-infection with other viruses. The agent detected may not be the definite cause of disease. Laboratories within the United States and its territories are required to report all results to the appropriate public health authorities. Negative results do not preclude SARS-CoV-2 infection and should not be used as the sole basis for patient management decisions. Negative results must be combined with clinical observations, patient history and epidemiological information. Negative results for SARS-CoV-2 RNA from saliva should be confirmed by testing of an alternative specimen type if clinically indicated. The Advanta Dx SARS-CoV-2 RT-PCR Assay is intended for use by qualified and trained clinical laboratory personnel specifically instructed and trained in the techniques of real-time PCR and in vitro diagnostic procedures. The Advanta Dx SARS-CoV-2 RT-PCR Assay is only for use under the Food and Drug Administration’s Emergency Use Authorization.

The Advanta Dx SARS-CoV-2 RT-PCR Assay is for 
In Vitro
 Diagnostic Use. It is for Use Under Emergency Use Authorization Only. Rx Only. It has not been FDA cleared or approved. It has been authorized by FDA under an EUA for use by authorized laboratories. It has been authorized only for the detection of nucleic acid from SARS-CoV-2, not for any other viruses or pathogens. It is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner. Other Fluidigm products are For Research Use Only. Not for use in diagnostic procedures.

About Fluidigm

Fluidigm (Nasdaq:FLDM) focuses on the most pressing needs in translational and clinical research, including cancer, immunology, and immunotherapy. Using proprietary CyTOF^® and microfluidics technologies, we develop, manufacture, and market multi-omic solutions to drive meaningful insights in health and disease, identify biomarkers to inform decisions, and accelerate the development of more effective therapies. Our customers are leading academic, government, pharmaceutical, biotechnology, plant and animal research, and clinical laboratories worldwide. Together with them, we strive to increase the quality of life for all. For more information, visit fluidigm.com.

Fluidigm, the Fluidigm logo, Advanta, Biomark, and CyTOF are trademarks and/or registered trademarks of Fluidigm Corporation in the United States and/or other countries. All other trademarks are the sole property of their respective owners.

Fluidigm’s ongoing collaboration with the Defense Advanced Research Projects Agency (DARPA) and its Epigenetic CHaracterization and Observation (ECHO) program includes financial support for development of innovative programs based on our microfluidics technology.

About Phase2 Labs

Phase2 Labs, based in Nashville, Tenn., is the nation’s first commercial molecular laboratory dedicated to the diagnostic management of acute and chronic respiratory diseases including COVID-19, ARDS, Chronic Obstructive Pulmonary Disease (COPD), moderate to severe asthma, interstitial lung disease, and cystic fibrosis. We employ our expertise in respiratory pathology to provide testing and measurement services for SARS-CoV-2. By taking a proactive approach to the research and analysis of COVID-19, we are building toward higher quality and better services for those who suffer long-term respiratory concerns. This further equips us in the contemporary research for the development of new pharmaceutical products. For more information, visit: www.phase2laboratories.com

Forward-Looking Statements for Fluidigm

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, among others, statements regarding potential impact of a Fluidigm program on U.S. COVID-19 testing availability and distribution of Fluidigm’s Advanta Dx SARS-CoV-2 RT-PCR Assay. Forward-looking statements are subject to numerous risks and uncertainties that could cause actual results to differ materially from currently anticipated results, including but not limited to risks relating to the potential adverse effects of the coronavirus pandemic on our business and operating results; the possible loss of key employees, customers, or suppliers; uncertainties in contractual relationships; our ability and/or the ability of the research institutions utilizing our products and technology to obtain and maintain Emergency Use Authorization from the FDA and any other requisite approvals to use our products and technology for diagnostic testing purposes; potential changes in priorities or requirements for Emergency Use Authorizations; potential limitations of any Emergency Use Authorization; potential changes in the priorities of government agencies; challenges inherent in developing, manufacturing, launching, marketing, and selling new products; risks relating to company research and development and distribution plans and capabilities; interruptions or delays in the supply of components or materials for, or manufacturing of, Fluidigm products; potential product performance and quality issues; intellectual property risks; and competition. Information on these and additional risks and uncertainties and other information affecting Fluidigm business and operating results is contained in Fluidigm’s Annual Report on Form 10-K for the year ended December 31, 2019, and in its other filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. Fluidigm disclaims any obligation to update these forward-looking statements except as may be required by law.

Available Information

We use our website (fluidigm.com), investor site (investors.fluidigm.com), corporate Twitter account (@fluidigm), Facebook page (facebook.com/Fluidigm), and LinkedIn page (linkedin.com/company/fluidigm-corporation) as channels of distribution of information about our products, our planned financial and other announcements, our attendance at upcoming investor and industry conferences, and other matters. Such information may be deemed material information, and we may use these channels to comply with our disclosure obligations under Regulation FD. Therefore, investors should monitor our website and our social media accounts in addition to following our press releases, SEC filings, public conference calls, and webcasts.

Fluidigm

Media:
Mark Spearman
Senior Director, Corporate Communications
650 243 6621

[email protected]

Investors:
Agnes Lee
Vice President, Investor Relations
650 416 7423

[email protected]

 

 

Company’s Hedging Strategy Proves Sound During COVID-19 Pandemic

HOUSTON, TX, Nov. 17, 2020 (GLOBE NEWSWIRE) — via NewMediaWire — Viking Energy Group, Inc. (OTCQB: VKIN) (“Viking” or the “Company”), an independent exploration and production company, is pleased to share certain financial results for the quarter ended September 30, 2020.

Key Financial Highlights for Q-3 2020 (all figures are approximate):         

• Revenues were $10.15 million as compared to $9.00 million in Q-3 2019.
• Net Loss was ($18.03 million) as compared to net income of $1.42 million in Q-3 2019, the majority of which loss was attributable to non-cash items, including:
  • a Change in the Fair Value of the Company’s Derivatives (i.e. hedging contracts) ($5.02 mm);
  • Amortization of Debt Discount ($3.23 mm);
  • Value of Stock issuances ($3.24 mm);
  • Depreciation, depletion and amortization ($2.57 mm); and
  • Impairment of Oil Properties due to drop in commodity prices ($2.50 mm)
• Adjusted EBITDA was $3.97 million for the three-month period ended Sept. 30, 2020 as compared to $4.38 million for the three-month period ended Sept. 30, 2019.
• Adjusted EBITDA for the nine-month period ending Sept. 30, 2020 was $14.02 million, as compared to $14.72 million for the nine-month period ending September 30, 2019.

James Doris, Viking’s President and Chief Executive Officer, commented, “We are extremely pleased with our Q3 results, especially given the unprecedented conditions during the period, namely the combined effect of the pandemic, regional weather issues, political uncertainty and general economic instability.”

About Viking Energy Group,
 Inc.
Viking is an independent exploration and production company focused on acquiring, enhancing and developing oil and natural gas properties in the Gulf Coast and Mid-Continent regions. The company has assets in Texas, Louisiana, Mississippi and Kansas.  For additional information, please visit: https://www.vikingenergygroup.com.

Financial Results for the Nine Months Ended September 30, 2018, 2019 and 2020 (unaudited):

		Summary Financial Results
		For the Nine Months Ended September 30,
		2018		2019		2020
Total Revenue – Oil and Gas		$        6,376,501		$      27,081,506		$      31,487,202
Lease Operating Costs (LOE)		2,957,073		9,004,334		13,147,640
Revenue in excess of lease operating costs		$        3,419,428		$      18,077,172		$      18,339,562
LOE as a % of Total Revenue		46%		33%		42%
Revenue in excess of lease operating costs as a % of Total Revenue		54%		67%		58%

Note:  The figures referenced in the summaries above are approximate and in most cases have been rounded to the nearest $100,000.  For specific amounts, please refer to
Viking’s Quarterly Report on Form 10-Q filed on November 16, 2020 with the Securities and Exchange Commission and available under “Investors — SEC Filings” at


www.vikingenergygroup.com



.

ADJUSTED EBITDA (unaudited):

					Adjusted EBITDA
					For the Three Months Ended September 30,
					2018		2019		2020
Net Income (Loss)					$      (2,944,764)		$           1,419,130		$        (18,034,807)
Non-Cash / Non-Operating Items
	Stock Based Compensation				680,156		402,451		3,235,200
	Changes in Fair Value of Derivatives				342,318		(5,539,255)		5,018,338
	Interest expense including amortization of debt discount				1,676,458		5,642,912		8,556,049
	Accretion – ARO				40,081		72,042		119,659
	Income tax benefit (expense)				(33,548)		–		–
	Impairment of oil and gas properties				–		–		2,500,000
	Depreciation, Depletion & Amortization				412,669		2,379,725		2,573,183
Total Non-Cash Items					3,118,134		2,957,875		22,002,429
Adjusted EBITDA					$           173,370		$           4,377,005		$           3,967,622
					Adjusted EBITDA
					For the Nine Months Ended September 30,
					2018		2019		2020
Net Income (Loss)					$      (8,452,863)		$          (9,220,005)		$        (15,458,598)
Non-Cash / Non-Operating Items
	Stock Based Compensation				1,898,255		444,533		3,686,582
	Changes in Fair Value of Derivatives				1,330,102		(267,688)		(8,569,093)
	Interest expense including amortization of debt discount				5,276,946		16,550,129		22,826,768
	Accretion – ARO				137,858		230,269		360,937
	Income tax benefit (expense)				(910,827)		–		–
	Impairment of oil and gas properties				–		–		2,500,000
	Depreciation, Depletion & Amortization				1,362,306		6,978,604		8,671,593
Total Non-Cash Items					9,094,640		23,935,847		29,476,787
Adjusted EBITDA					$           641,777		$         14,715,842		$         14,018,189

Adjusted EBITDA – Non-GAAP Financial Measures

This press release contains “Adjusted EBITDA”, a non-GAAP financial measure. The Company defines Adjusted EBITDA as net income (loss), adjusted for certain non-cash and non-operating items, such as stock-based compensation, changes in the fair value of derivative instruments, asset retirement obligation accretion expense, depreciation, depletion and amortization, interest expense and income tax (benefit) provision.  We also exclude certain other non-cash items listed in the aforementioned table. Management believes the presentation of Adjusted EBITDA is useful because it allows external users of our financial statements, such as industry analysts, investors, lenders and rating agencies, to compare the results of our operations from period to period without regard to our financing methods or capital structure, and to have access to the same metrics that management uses to evaluate the Company’s performance. Adjusted EBITDA is not a measure of financial performance under US GAAP and should be considered in addition to, not as a substitute for, net income (loss). The Company adjusts net income (loss) for these specific items to arrive at Adjusted EBITDA because they can vary substantially from company to company within the Company’s industry depending upon accounting methods and book values of assets, capital structures and the method by which the assets were acquired.  Adjusted EBITDA should not be considered as an alternative to, or more meaningful than, net income (loss) as determined in accordance with GAAP or as an indicator of the Company’s liquidity. Certain items excluded from Adjusted EBITDA are significant components in understanding and assessing the Company’s financial performance, such as cost of capital and tax structure, as well as the historic costs of depreciable assets, none of which are components of Adjusted EBITDA. The Company’s computation of Adjusted EBITDA may not be comparable to other similarly titled measures of other companies or to such measure in our credit facility or any of our other contracts.

Forward-Looking Statements

This press release may contain forward-looking information within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended. Any statements that are not historical facts contained in this press release are “forward-looking statements”, which statements may be identified by words such as “expects,” “plans,” “projects,” “will,” “may,” “anticipates,” “believes,” “should,” “intends,” “estimates,” and other words of similar meaning. Such forward-looking statements are based on current expectations, involve known and unknown risks, a reliance on third parties for information, transactions that may be cancelled, and other factors that may cause our actual results, performance or achievements, or developments in our industry, to differ materially from the anticipated results, performance or achievements expressed or implied by such forward-looking statements. Factors that could cause actual results to differ materially from anticipated results include risks and uncertainties related to the fluctuation of global economic conditions or economic conditions with respect to the oil and gas industry, the COVID-19 pandemic, the performance of management, actions of government regulators, vendors, and suppliers, our cash flows and ability to obtain financing, competition, general economic conditions and other factors that are detailed in our filings with the Securities and Exchange Commission (“SEC”), including our Annual Report on Form 10-K for the year ended December 31, 2019, and our Quarterly Reports on Form 10-Q or 10-Q/A, as applicable, for the quarters ended March 31, 2020, June 30, 2020 and September 30, 2020. We intend that all forward-looking statements be subject to the safe-harbor provisions.

Contact Information


Investors and Media:
Tel. 281.404.4387 (ext.5)
[email protected]

HOUSTON, Nov. 17, 2020 (GLOBE NEWSWIRE) — C-Bond Systems (the “Company” or “C-Bond”) (OTC: CBNT), a nanotechnology solutions company, announced today that it has reported its financial results for the third quarter ended September 30, 2020, including record quarterly revenue and positive net income inclusive of a one-time gain attributable to the extinguishment of the Company’s convertible debt.

Thir
d Quarter 2020 and Subsequent Operational Highlights

• Achieved record quarterly revenue of $253,000.
• Repaid in full all convertible debt and redeemed all Series A Convertible Preferred Stock.
• Entered into a $1.2 million supply agreement with an international distributor for C-Bond nanoShield™ and received an initial purchase order in excess of $100,000. This distributor must purchase at least an additional $1.1 million of C-Bond nanoShield in 2021 to maintain exclusivity in the 10 countries it operates.
• Entered into a $1 million exclusive distribution agreement for MB-10 Tablets and FN Nano products with a prominent distributor in India. This distributor must purchase at least $1 million of the Company’s disinfection products in 2021 to maintain exclusivity in India.
• Received an initial purchase order for MB-10 Tablets in excess of $80,000 from a Southeast Asian distributor.
• Entered into a supply agreement with a leading national vehicle protection solutions provider to private label C-Bond nanoShield.
• Announced a distribution agreement with F&I provider American Guardian Warranty Solutions for C-Bond nanoShield.

Management Commentary

“The third quarter of 2020 was very significant for the Company as we achieved record quarterly revenue and repaid in full all outstanding convertible debt,” said Scott R. Silverman, Chairman and Chief Executive Officer of C-Bond Systems. “We also entered into noteworthy international distribution agreements for C-Bond nanoShield and MB-10 Tablets during the third quarter, which will allow us to expand our global reach and grow our business. Here in the U.S., we are pleased with the increased adoption by F&I (finance and insurance) and vehicle warranty solutions providers of C-Bond nanoShield and look forward to continued momentum in this sector.”

Third Quarter 2020 Financial Summary

For the three months ended September 30, 2020, sales totaled $252,940, compared to $171,383 for the three months ended September 30, 2019, an increase of 47.6%. The increase was primarily attributable to an increase in the sale of disinfection products and an increase in C-Bond nanoShield solution sales.

Operating expenses totaled $852,760 for the quarter ended September 30, 2020, compared to $1,534,401 for the three months ended September 30, 2019, a decrease of 44.4%. Compensation and related benefits decreased by $623,665, or 49.8%, for the three months ended September 30, 2020, compared to the three months ended September 30, 2019. This decrease was primarily due to a decrease in stock-based compensation of $640,700 during the three months ended September 30, 2020.

Operating loss during the three months ended September 30, 2020, decreased by $727,790, or 52.2%, compared to the three months ended September 30, 2019.

For the three months ended September 30, 2020, other income, net, amounted to $1,145,854, compared to other expenses, net of $(408,417) for the three months ended September 30, 2019, a positive change of $1,554,271, or 380.6%. This change was due to a change in derivative income (expense) of $1,034,410 attributable to the recording of or extinguishment of derivative liabilities related to convertible debt and by the recording of a gain from debt extinguishment of $736,406 related to the conversion of convertible debt, offset by an increase in interest expense of $216,545 related to the amortization of debt discount, an increase in interest-bearing debt, and an increase in interest expense related to accretion of debt discount related to Series A preferred shares.

Net income for the quarter was $480,396, or $0.00 per common share (basic and diluted) for the three months ended September 30, 2020, compared to a net loss of $(1,801,665), or $(0.02) per common share (basic and diluted), for the three months ended September 30, 2019, a positive change of $2,282,061. This positive change was primarily attributable to an increase in gross profit, a decrease in operating expenses, and an increase in other income, net, as discussed above.

About C-Bond

C-Bond Systems, Inc. (OTC: CBNT) is a Houston-based advanced nanotechnology company and marketer of the patented C-Bond technology, developed in conjunction with Rice University and independently proven to significantly strengthen glass in key automotive and structural applications. The Company’s Transportation Solutions Group sells C-Bond nanoShield, a liquid solution applied directly to automotive windshields, sold through distributors. The Company’s Safety Solutions Group sells ballistic-resistant glass solutions and FN NANO Coating directly to private enterprises, schools, hospitals and government agencies. For more information, please visit our website: www.cbondsystems.com, Facebook: https://www.facebook.com/cbondsys/ and Twitter: https://twitter.com/CBond_Systems.

Forward-Looking Statements

Statements in this press release about our future expectations
,
including the likelihood that
the distributor must p
urchase an additional $1.1 million of product in 2021 to maintain exclusivity in 10 countries
;
the likelihood that our
distributor
in India
must purchase at least $1 million of
our
disinfection products in 2021 to maintain exclusivity in India
;
the likelihood that
our
international distribution agreements for C-Bond nanoShield and MB-10 Tablets will allow us to expand our global reach and grow our business
; the likelihood that we will experience
continued momentum
among F&I and vehicle warranty solutions providers
;
c
onstitute “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Litigation Reform Act of 1995. Such forward-looking statements involve risks and uncertainties and are subject to change at any time, and our actual results could differ materially from expected results. These risks and uncertainties include, without limitation, C-Bond’s ability to raise capital; the Company’s ability to successfully commercialize its products;
the effect of the COVID-19
global pandemic
on the Company’s ability to operate;
as well as other risks. Additional information about these and other factors may be described in the Company’s filings with the Securities and Exchange Commission (“SEC”) including its Form 10-K filed on March 25, 2020, its Forms 10-Q filed on
November 16, 2020,
August 14, 2020,
and
May 15, 2020,
and in future filings with the SEC. The Company undertakes no obligation to update or release any revisions to these forward-looking statements to reflect events or circumstances after the date of this statement or to reflect the occurrence of unanticipated events, except as required by law.

Contact:

Allison Tomek
C-Bond Systems
6035 South Loop East
Houston, TX 77033
[email protected]

Brokers and Analysts:
Chesapeake Group
410-825-3930
[email protected]

–
Landsea Homes
Reports Strong Growth Across
Nearly All
Financial and Operational Metrics
–

– Remains on Track to Complete Business Combination in the Fourth Quarter of 2020 –

NEW YORK, Nov. 17, 2020 (GLOBE NEWSWIRE) — LF Capital Acquisition Corp.’s (NASDAQ: LFAC) (“LF Capital”) business combination target, Landsea Homes Incorporated (“Landsea Homes” or the “Company”), is reporting unaudited financial results for the third quarter ended September 30, 2020. The unaudited results are subject to completion of Landsea Homes’ quarterly financial reporting process and the preparation of the unaudited financial statements for the quarter.

Third Quarter 2020 Highlights
Compared to Third Quarter 2019

• Total revenue increased 78% to a third quarter record of $218.5 million (including revenue from Garrett Walker Homes (“GWH”) in the third quarter of 2019, total revenue increased organically by 56% in the third quarter of 2020 compared to the pro forma prior year period)
• Net income attributable to Landsea Homes increased 71% to $3.2 million
• Adjusted net income attributable to Landsea Homes (a non-GAAP measure) increased 73% to $9.8 million
• Adjusted EBITDA (a non-GAAP measure) increased 86% to $20.3 million
• Net new home orders increased 175% to a third quarter record of 504 homes
• Homes in backlog grew 262% to a Company record of 922 homes with a dollar value of $439.6 million

Management Commentary

“We continued our strong momentum in the third quarter, reporting record results and growth across nearly every financial metric,” said John Ho, CEO of Landsea Homes. “Throughout the quarter, we remained aggressive in our expansion, bringing our total lots owned or controlled to nearly 7,000 while building our robust backlog of homes to almost 1,000. Homebuyers are also responding well to our unique home differentiators, including both our High Performance Homes and our newly introduced, highly adaptable LiveFlex home offerings. As we look ahead, we are incredibly optimistic about the growth opportunities on the horizon.”

Scott Reed, CEO and President of LF Capital, commented: “As we near the completion of our business combination, I am pleased by the strong results Landsea Homes delivered in the third quarter, which reconfirms our excitement about our partnership. The Company has established itself as a growth-oriented homebuilder with a unique value proposition designed to accommodate the evolving needs of today’s homebuyers. With strong industry tailwinds at our backs and a robust financial profile poised for expansion, I look forward to consummating the business combination and bringing Landsea Homes into its next chapter of growth as a public company.”

Third Quarter 2020 Financial
Results

Total revenue increased 78% to $218.5 million compared to $123.0 million in the third quarter of 2019. Including revenue from GWH, which was acquired in January 2020, in the third quarter of 2019, total revenue increased 56% in the third quarter of 2020 compared to the pro forma prior year period.

Net new home orders increased 175% to 504 homes with a dollar value of $279.1 million and an average sales price of $554,000 compared to 183 homes with a dollar value of $155.5 million and an average sales price of $850,000 in the prior year period. Including net new home orders from GWH in the third quarter of 2019, orders increased 46% in the third quarter of 2020 compared to the pro forma prior year period. The decline in average sales price in conjunction with the growth in new home orders and dollar value is a result of the company’s strategic shift to selling a higher volume of entry-level and move-up homes and having more orders in Arizona which have a lower price point, along with the discounting of select homes as a result of COVID-19 related uncertainties.

Total backlog increased to 922 homes with a dollar value of $439.6 million and an average sales price of $477,000 in the third quarter of 2020 compared to 255 homes with a dollar value of $231.9 million and an average sales price of $909,000 in the prior year period. The decline in average sales price was driven by a higher percentage of the backlog in geographies with lower price points and a greater number of entry-level and move-up homes. Total lots owned or controlled increased 7% to 6,838 compared to the 6,390 at June 30, 2020, and 45% compared to 4,724 at December 31, 2019.

Adjusted home sales gross margin (a non-GAAP measure) was 20.4% compared to 23.2% in the prior year period. The decline was a result of COVID-related incentives and slightly higher job site operating costs due to CDC protocols.

Net income attributable to Landsea Homes increased 71% to $3.2 million compared to $1.9 million in the prior year period. Adjusted net income attributable to Landsea Homes (a non-GAAP measure) increased 73% to $9.8 million compared to $5.6 million in the prior year period. The improvement was primarily driven by the aforementioned increase in revenue, along with a decline in total operating expenses as a percentage of total revenue.

Adjusted EBITDA (a non-GAAP measure) increased 86% to $20.3 million compared to $10.9 million in the prior year period, primarily as a result of the aforementioned increase in top-line growth and continuing to more efficiently leverage SG&A costs.

At September 30, 2020, cash and cash equivalents totaled $84.9 million compared to $154.0 million at December 31, 2019. Total debt was $309.2 million at September 30, 2020, compared to $190.0 million at December 31, 2019. Landsea Homes’ net debt to net book capitalization was 30.1% at September 30, 2020, compared to 5.4% at December 31, 2019.

LF Capital and Landsea Homes remain on track to close the business combination in the fourth quarter of 2020.

About LF Capital Acquisition Corp.

LF Capital Acquisition Corp. is a blank check company that was formed in 2018 for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. For more information, please visit www.lfcapital.co.

About Landsea Homes Incorporated.

Landsea Homes designs and builds best-in-class, high-performance homes and sustainable master-planned communities in some of the most desirable markets in the United States. The company has developed homes and communities in, Arizona and throughout California in Silicon Valley, Los Angeles and Orange County.

Creating inspired places that reflect modern living, Landsea Homes builds suburban, single-family detached and attached homes, mid- and high-rise properties and master-planned communities to meet the diverse and ever-changing expectations and lifestyles of our homebuyers today and tomorrow.

Led by a veteran team of industry professionals who boast years of worldwide experience and deep local expertise, Landsea Homes is committed to positively enhancing the lives of our homebuyers, employees and stakeholders by creating an unparalleled lifestyle experience that is unmatched everywhere we build.

Landsea Homes is currently a wholly owned U.S. subsidiary of Landsea Green Group, an international homebuilder that thinks globally but operates locally. Operating on three continents including Europe, Asia and North America, Landsea Green’s deep knowledge and experience of building and living in different environments all over the world deliver homes that embrace the local lifestyle in which they are built. For more information, please visit landseahomes.com.

Important Information About the Proposed Merger and Related Transactions and Where to Find It

LF Capital filed with the Securities and Exchange Commission (“SEC”) a preliminary proxy statement in connection with the special meeting of stockholders to be held to approve the proposed merger and related transactions as of a record date to be established for voting on such proposals and will mail the definitive proxy statement and other relevant documents to its stockholders. Investors and security holders of LF Capital are advised to read the preliminary proxy statement and any amendments thereto, and once available, the definitive proxy statement, because these documents contain and will contain important information about the proposed merger and related transactions and the parties to such transactions. Stockholders of LF Capital will also be able to obtain copies of the preliminary or definitive proxy statement, once available, as well as other documents filed with the SEC by LF Capital, without charge, once available, at the SEC’s website at www.sec.gov or by directing a request to: LF Capital Acquisition Corp., 600 Madison Avenue, Suite 1802, New York, NY 10022.

Participants in the Solicitation

LF Capital and its directors, executive officers, other members of management, and employees, under SEC rules, may be deemed to be participants in the solicitation of proxies of LF Capital’s stockholders in connection with the proposed merger and related transactions. Investors and security holders may obtain more detailed information regarding the names and interests in the proposed transactions of LF Capital’s directors and officers in LF Capital’s filings with the SEC, including LF Capital’s Annual Report on Form 10-K for the fiscal year ended December 31, 2019, which was filed with the SEC on February 24, 2020 and such information in the preliminary proxy statement and amendments thereto filed with the SEC by LF Capital in connection with the proposed merger and related transactions.

Forward Looking Statements

This press release includes “forward looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. When used in this press release, the words “estimates,” “projected,” “expects,” “anticipates,” “forecasts,” “plans,” “intends,” “believes,” “seeks,” “may,” “will,” “should,” “future,” “propose” and variations of these words or similar expressions (or the negative versions of such words or expressions) are intended to identify forward-looking statements. These forward-looking statements are not guarantees of future performance, conditions or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside LF Capital’s management’s control, that could cause actual results or outcomes to differ materially from those discussed in the forward-looking statements. Important factors, among others, that may affect actual results or outcomes include: the conditions to the completion of the merger, including the required approval by LF Capital’s stockholders, may not be satisfied on the terms expected or on the anticipated schedule; the parties’ ability to meet expectations regarding the timing and completion of the merger; the occurrence of any event, change or other circumstance that could give rise to the termination of the Merger Agreement; the approval by LF Capital’s stockholders of an amendment to LF Capital’s organizational documents to extend the date by which LF Capital must complete its initial business combination in order to have adequate time to close the proposed transaction; the outcome of any legal proceedings that may be instituted against the Company related to the merger or the Merger Agreement; and the amount of the costs, fees, expenses and other charges related to the merger. LF Capital undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

No Offer or Solicitation

This press release shall not constitute a solicitation of a proxy, consent or authorization with respect to any securities or in respect of the proposed transaction. This press release shall also not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any states or jurisdictions in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offering of securities shall be made except by means of a prospectus meeting the requirements of section 10 of the Securities Act of 1933, as amended.

Non-GAAP Financial Metrics

This joint press release contains certain financial information determined by methods other than in accordance with accounting principles generally accepted in the United States (“GAAP”). Any non-GAAP financial measures and other non-GAAP financial information used in this presentation are in addition to, and should not be considered superior to, or a substitute for, financial measures prepared in accordance with GAAP. Non-GAAP financial measures and other non-GAAP financial information is subject to significant inherent limitations.

We believe that the disclosure of these “non-GAAP” financial measures presents additional information which, when read in conjunction with our consolidated financial statements prepared in accordance with GAAP, assists in analyzing our operating performance and the proposed merger and related transactions. Additionally, we believe this financial information is utilized by regulators and market analysts to evaluate a company’s financial condition, and therefore, such information is useful to investors. The non-GAAP financial measures should not be viewed as substitutes for operating results determined in accordance with GAAP, nor are they necessarily comparable to non-GAAP performance measures that may be presented by other companies.

This press release also includes certain estimates of non-GAAP measures, including with respect to expected third quarter 2020 results. Due to the high variability and difficulty in making accurate estimates of some of the information excluded from these non-GAAP measures, together with some of the excluded information not being ascertainable or accessible, Landsea Homes is unable to quantify certain amounts that would be required to be included in the most directly comparable GAAP financial measures without unreasonable effort. Consequently, no disclosure of estimated comparable GAAP measures is included and no reconciliation of the forward-looking non-GAAP financial measures is included.

LF Capital Contact:

Scott A. Reed
Chief Executive Officer and President
214-740-6112

Landsea Homes Contact:

John Ho
Chief Executive Officer
949-345-8080

Investor Relations Contact:

Cody Slach
Gateway Investor Relations
949-574-3860
[email protected]

VANCOUVER, British Columbia, Nov. 17, 2020 (GLOBE NEWSWIRE) — Golden Predator Mining Corp. (TSX.V:GPY, OTCQX:NTGSF) (the “Company”) today announces the completion of its 2020 work program at its licensed 100%-owned Brewery Creek mine project ‎located approximately 55 km by road from Dawson City, Yukon. The 2020 program consisted of 60 drill holes for ~5,600 m of drilling including ~ 4,400 m of exploration and in-fill drilling plus 1,200 m of metallurgical and geotechnical drilling. All samples have been shipped and are currently being processed.

Brewery Creek maps can be viewed at: https://www.goldenpredator.com/_resources/news/GPY-NR-2020-Drill-Program-Completed-MAPS.pdf.

2020 Exploration and Technical Drill Program
The 2020 Brewery Creek drill program consisted of exploration, in-fill, geotechnical, hydrogeologic and metallurgical drilling to advance the Bankable Feasibility Study currently underway and projected for completion in Q1/21.

In
f
ill Drilling

This program builds on Golden Predator’s successful 2019 program that established continuity of mineralization within the licensed Reserve Trend between the eastern edge of the Canadian-Fosters-Kokanee-Golden pits east to the Lucky pit. The 32 reverse circulation drill holes drilled in 2020 were designed to fill in and expand the gold resource between the eastern Golden zone and western Lucky zone. The targeted mineralization between these zones has been offset by a high-angle normal fault and was previously untested until 2019 when the zone was intersected with multiple drill holes. 

Infill drilling within this 400 m gap between the eastern edge of the Fosters to Golden trend and the western edge of the Lucky zone is also to increase the density of drilling to convert Inferred resources to Indicated resources and confirm continuity of mineralization between the two deposits while testing for additional resources. The goal is to establish and confirm continuous mineralization along the Fosters-Canadian-Kokanee-Golden-Lucky zones for mine design now in progress as a part of the Brewery Creek Bankable Feasibility Study (BFS).

A total of 32 reverse circulation drill holes totaling 3,706 m were completed in the gap area between the eastern edge of Golden and western edge of Lucky. Samples from this program have been submitted to ALS Laboratories for sample preparation in Whitehorse, Yukon and assaying in Vancouver, British Columbia. Initial assay results from the program are expected in late November with complete assay results expected by the end of the year.

2020 Exploration Drilling of New Large-Scale Targets – Classic and Lonestar Zone
The 2020 drill program, targeted newly defined extensions of the Classic/Lone Star porphyry-style intrusive, with 3 reverse circulation holes totaling 687 m. The holes were very wide step-out holes drilled at significant distances from any existing drilling at the Classic and Lone Star areas.

Two of the drill holes (RC20-2710 and RC20-2711) were located approximately 500 m from each other and at least 650 m southeast of the closest previous drilling within the Classic and Lone Star zones. These holes targeted an area defined by anomalous gold and arsenic soil and rock chip geochemistry within a structural zone. The third drill hole (RC20-2711), located approximately 1,330 m to the east of the nearest previous drilling, tested a coincident aeromagnetic and radiometric anomaly indicating a structural zone along the margin of a biotite monzonite intrusive within an area of spotty gold and arsenic in soil geochemistry. All three drill holes encountered multiple fault zones and variable amounts of intrusive rock as dikes/sills within the structural zones.

The Classic Zone is a near surface bulk tonnage target that lies approximately 3 km south of the Brewery Creek Reserve Trend. Together with the Lone Star zone, the Classic Zone demonstrates the discovery potential of the entire southern portion of the large Brewery Creek Property where a large syenite intrusion hosts gold mineralization primarily in sheeted quartz/carbonate/pyrite veins and as fine-grained disseminations. Initial column leach tests have indicated that this intrusive hosted mineralization is leachable to at least a 200 m depth. This mineralization is clearly a separate younger mineralizing event not associated with the quartz monzonite thrust-hosted mineralization historically exploited in the Reserve Trend which is the subject of the ongoing bankable feasibility study.

Metallurgical
& Geotechnical
Drilling
A total of 14 PQ diamond drill holes totaling 540 m were completed in Foster-Canadian-Kokanee-Golden and Lucky pit areas. The program was designed to obtain mineralized material from the Fosters, Kokanee, Golden and Lucky areas for additional column leach tests. The core was shipped to McClelland Labs in Reno, NV where it is currently being tested. The core samples will be used to conduct additional column leach tests at a coarser crush size of approximately 3/4” versus previous test work conducted at 3/8” crush size at Kokanee, Golden and Lucky. These column tests are being conducted to confirm the recent results of column leach tests run at various crush sizes on material from the historic heap leach pad where the data showed slightly better recoveries of gold in solution for the coarser 3/4” crush size. A coarser crush size would help streamline any recovery process. These tests will be detailed in the Bankable Feasibility Study currently underway.

A total of eleven geotechnical/hydrogeologic drill holes were completed to support the ongoing Bankable Feasibility Study at Brewery Creek. A total of 975 m of drilling was completed in 8 diamond drill holes (792 m) and 3 reverse circulation drill holes (182 m). The diamond drill program was consisted of oriented, HQ3 core to support detailed fracture analysis of lithologies in the proposed pit walls and three of these were completed with piezometers. The 3 reverse circulation drill holes were drilled and completed as hydrogeologic monitor wells.

Brewery Creek Mine: Resources¹

2020 Brewery Creek Mineral Resource Estimate (1)
Leachable	Tonnes	g/t	Gold Oz.
Indicated	22,200,000	1.11	789,000
Inferred	16,800,000	0.92	497,000
Sulphide	Tonnes	g/t	Gold Oz.
Inferred	30,600,000	0.84	828,000

<sup>Materials
on the heap leach pad were not included in the resource update.



Mineral Resources estimates conducted within a pit shell developed at $2
,
000/oz gold with an internal cut-off grade calculated at $1
,
500/oz gold was used to report mineral resource inventories.</sup>

The resource estimate is based on a recovery model created from assay data, bottle and column leach test work and historic recovery analysis instead of a less accurate visual oxide-sulfide boundary developed from geologist drill logs. Sedimentary and intrusive rocks, which have distinct metallurgical characteristics, were estimated separately based on gold-grade distribution analysis.

The current 2020 Mineral Resources Estimate supersedes the 2019 Mineral Resource Estimate. A supporting NI 43-101 Technical Report is filed on SEDAR at www.sedar.com.‎

Brewery Creek Mine Work Plan
The Brewery Creek Mine is a licensed brownfields heap leach gold mine that was operated by Viceroy Minerals Corporation from 1996 to 2002. Brewery Creek is authorized to restart mining activities as defined within the Quartz Mining License and Water License. The Company intends to resume mining and processing of licensed deposits when supported by an independent study that outlines technical and economic viability. The 180 km² property is located 55 km east of Dawson City and is accessible year-round by paved and improved gravel roads. Significant infrastructure remains in place, allowing for a timely restart schedule under existing operating licenses.

A Bankable Feasibility Study (BFS) is being conducted by Kappes Cassiday & Associates of Reno, Nevada which will include a multi-year mine plan for the advancement of the Brewery Creek project. The BFS will include an inventory of the mineralized material remaining on the heap and mine planning (completed by Tetra Tech Inc of Golden, Colorado) for the resumption of the mining of material from leachable resources contained within the licensed area and reported in the Company’s Mineral Resource Estimate. The BFS will include all the key parameters involved in reconstructing or adding necessary infrastructure including a crushing facility, the Adsorption-Desorption-Recovery (“ADR”) plant and assay lab and an implementation schedule, sourcing, and economic cash flow model sufficiently detailed to move directly into procurement, development and construction if economically warranted. Any production decisions would be dependent on the outcome of a study demonstrating positive technical and economic viability.

The technical content of this news release has been reviewed and approved by Michael Maslowski, CPG, a Qualified Person as defined by National Instrument 43-101 and is employed by the Company as its Chief Operating Officer.

About Golden Predator Mining Corp.
Golden Predator is advancing the past-producing Brewery Creek Mine towards a timely resumption of mining activities, under its Quartz Mining and Water Licenses, in Canada’s Yukon. With established resources grading over 1.0 g/t gold the Company is completing a Bankable Feasibility Study for the restart of heap leach operations. The Brewery Creek Mine project operates with a Socio Economic Accord with the Tr’ondëk Hwëch’in First Nation.

For additional information:

Janet Lee-Sheriff

Chief Executive Officer

(604) 260-8435
[email protected]
www.goldenpredator.com

^{Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
No stock exchange, securities commission or other regulatory authority has approved or disapproved the information contained herein.
This press release contains forward-looking information that involve various risks and uncertainties regarding future events. Such forward-looking information can include without limitation statements based on current expectations
that the Brewery Creek will advance to an early production decision, or the extent of any additional mineral resource that could result from incorporating 2019 exploration drilling.
Actual results and future events could differ materially from those anticipated in such information. These and all subsequent written and oral forward-looking information are based on estimates and opinions of management on the dates they are made and are expressly qualified in their entirety by this notice. Except as required by law, the Company assumes no obligation to update forward-looking information should circumstances or management’s estimates or opinions change.}

1. The 2020 Mineral Resource Estimate was conducted in accordance with CIM guidelines and is reported in a NI 43-101 Technical Report which will be filed on SEDAR and the Company’s website within 45 days.

NEW YORK, Nov. 17, 2020 (GLOBE NEWSWIRE) — via InvestorWire –Brain Scientific Inc. (OTCQB: BRSF), a neurology-focused medical device and software company, has entered into an agreement with Europe’s leading certification and compliance company AFINA s.r.o. The agreement specifies that AFINA will act as an authorized representative for Brain Scientific in the European Union and assist with registering Brain Scientific’s advanced EEG solutions in 32 countries in the European market.

The next generation NeuroCap by Brain Scientific is a hospital-grade disposable EEG headset featuring 22 electrodes and 19 active EEG channels. The pre-gelled disposable cap removes the time-consuming task of placing electrodes and measuring the patient’s head, which gives both neurological technicians and clinical staffers the ability to provide immediate care. The NeuroCap works alongside Brain Scientific’s NeuroEEG™, an amplifier device to initiate the EEG studies in less than five minutes.

“We believe our next generation rapid EEG product will be an invaluable solution for hospitals and medical centers across the EU,” said Boris Goldstein, Chairman of the Board at Brain Scientific, Inc. “We are delighted to move towards the ultimate goal of distributing our NeuroCap in Europe.”

In the EU, neurological disorders are ranked third after cardiovascular diseases and cancers, representing 13.3% of total cases and 19.5% of total deaths. Stroke, dementias and headache are the three most common causes of DALYs – the Disability Adjusted Life Years in the EU, as measured by the World Health Organization.

Recent data
suggests that about 165 million people in Europe live with a brain disorder, and one in three people will suffer from some type of neurological or psychiatric disorder during their life. Other statistics show that the members of the European Union have invested a large portion of 800 billion euros spent on health in diagnostics and treatment of these disorders.

Brain Scientific’s disposable EEG devices are designed to address the growing need for neurological services globally. By introducing transformative brain diagnostic solutions that apply cutting edge technologies and establishing a new innovative norm for clinicians, Brain Scientific expects its products to provide a seamless testing process for neurology patients at the exact point-of-care.

About Brain Scientific

Brain Scientific
is a commercial-stage healthcare company with two FDA-cleared products, providing next-gen solutions to the neurology market. The Company’s smart diagnostic devices and sensors simplify administration, shorten scan time and cut costs, allowing clinicians to make rapid decisions remotely and bridge the widening gap in access to neurological care. To learn more about our corporate strategy, devices or for investor relations please visit: www.brainscientific.com or email us at [email protected].

Forward-Looking Statements

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Forward-looking statements, which involve assumptions and describe our future plans, strategies and expectations, are generally identifiable by use of the words “may,” “should,” “would,” “will,” “could,” “scheduled,” “expect,” “anticipate,” “estimate,” “believe,” “intend,” “seek” or “project” or the negative of these words or other variations on these words or comparable terminology. Such forward-looking statements are not meant to predict or guarantee actual results, performance, events or circumstances, and may not be realized because they are based upon the Company’s current projections, plans, objectives, beliefs, expectations, estimates, and assumptions, and are subject to several risks and uncertainties and other influences, many of which the Company has no control. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. Factors that may influence or contribute to the inaccuracy of the forward-looking statements or cause actual results to differ materially from expected or desired results may include, without limitation, the Company’s lack of capital and inability to obtain additional financing, the significant length of time and resources associated with the development of our products and related insufficient cash flows and resulting illiquidity, the Company’s inability to expand its business, significant government regulation of medical devices and the healthcare industry, lack of product diversification, volatility in the price of the Company’s raw materials and the Company’s failure to implement the Company’s business plans or strategies. These and other factors are identified and described in more detail in the Company’s filings with the SEC. The Company does not undertake to update these forward-looking statements.

Corporate Communications:

InvestorBrandNetwork (IBN)
Los Angeles, California
www.InvestorBrandNetwork.com
310.299.1717 Office
[email protected]

Burlington, Iowa, Nov. 17, 2020 (GLOBE NEWSWIRE) — Winegard, the company dedicated to bringing the greatest range of connectivity solutions to the world, announces today it has teamed up with leading cellular amplification manufacturer SureCall to release the powerful RangePro Cell Booster.

Building a holistic ecosystem for RVs

“The RangePro fills an important niche in Winegard’s growing RV connectivity ecosystem,” says Winegard President Grant Whipple. “It’s specifically designed to enhance voice, text, and 4G LTE data signals in weak service areas.

“We’re very excited to bring the RangePro to market in partnership with SureCall. This is a product that was previously unavailable to most RVers. Now they won’t have to worry about dropped or missed calls as they enjoy their travels.”

Reliable calls and texting

“I believe customers are going to love what the powerful RangePro can do for them,” says SureCall CEO Hongtao Zhan. “Our driving mission is to improve cellular connections for everyone, everywhere. When Winegard approached us to work on this project, we saw it as a unique opportunity to bring reliable cellular internet, calls, and texting to RV users. I couldn’t be happier with how the RangePro system has turned out.”

The RangePro Cell Booster starts at $499.00.

Features:

• Highest gain allowable on 3G & 4G LTE bands across all North American carriers
• Versatile and durable external mounting system designed to work with all RVs
• Industry-best 3-year warranty and lifetime tech support based in the USA

Learn more about the RangePro here. Available now for DIY or dealer installation.

RangePro is manufactured by SureCall in partnership with Pace International of Rochester, Minnesota.

About Winegard Company

Built on more than 60 years of heritage in Burlington, Iowa, Winegard Company is a trusted partner for delivering high-performance connectivity solutions. This includes WiFi, 4G LTE, 5G, satellite, IoT, broadband, video, and over-the-air technology for residential, commercial, and mobile.

About SureCall

Since its inception in 2001, SureCall has become a leader for cell phone signal boosters. SureCall combines its patented engineering, top-quality materials, and comprehensive lifetime support to provide cell-service solutions to mobile device users in their homes, offices, and vehicles.

About Pace International 

Pace International is an industry-leading distributor of telecommunications products. Founded in 1972, Pace is headquartered in Rochester, Minnesota.

Attachment

• Winegard RangePro Cellular Signal Booster

Daphne Rothlisberger
Winegard Company
+1 319 754 0761
[email protected]